Top Markets
Coin of the day
Catalent, Inc. Catalent, Inc.

Catalent, Inc.

CTLT
Clasificación en acciones #1925
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Precio por acción
$63.48
Última sincronización: 2024-12-17
Capitalización bursátil
$11.52B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Catalent, Inc. (CTLT)

Categoría

Ratio P/E de Catalent, Inc. (CTLT)
Ratio P/E al August 2026 TTM: -11.02
Según los últimos informes financieros y el precio de las acciones de Catalent, Inc., el P/E actual (TTM) de la empresa es -11.02. Al final de 2023, la empresa tenía un P/E de -33.83.
Historial del ratio P/E de Catalent, Inc. desde 2011 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) -11.02 13.03%
2024 -9.75 -71.19%
2023 -33.83 -189.39%
2022 37.84 21.87%
2021 31.05 -51.08%
2020 63.47 10.50%
2019 57.44 -12.63%
2018 65.74 64.52%
2017 39.96 55.29%
2016 25.73 55.29%
2015 16.57 -88.55%
2014 144.74 -388.22%
2013 -50.22 -47.75%
2012 -96.12 121.31%
2011 -43.43 0.00%
Relación P/E para empresas similares o competidores
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.